Showing 1 - 5 results of 5 for search 'Petros Christopoulos', query time: 0.03s Refine Results
  1. 1
    Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis

    Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis by Ann-Kathrin Daum, Lisa Schlicker, Marc A. Schneider, Thomas Muley, Ursula Klingmüller, Almut Schulze, Michael Thomas, Petros Christopoulos, Holger Sültmann

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer

    Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer by Florian Janke, Mateo Gasser, Arlou K. Angeles, Anja L. Riediger, Magdalena Görtz, Louise Appenheimer, Astrid K. Laut, Simon Ogrodnik, Sabrina Gerhardt, Albrecht Stenzinger, Marc A. Schneider, Michael Thomas, Petros Christopoulos, Holger Sültmann

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Fractionated stereotactic radiotherapy of brainstem metastases – Clinical outcome and prognostic factors

    Fractionated stereotactic radiotherapy of brainstem metastases – Clinical outcome and prognostic factors by Anna Krämer, Laura Hahnemann, Fabian Schunn, Christoph A. Grott, Michael Thomas, Petros Christopoulos, Jonathan W. Lischalk, Juliane Hörner-Rieber, Philipp Hoegen-Saßmannshausen, Tanja Eichkorn, Maximilian Y. Deng, Eva Meixner, Kristin Lang, Angela Paul, Fabian Weykamp, Jürgen Debus, Laila König

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study

    NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, si... by Albrecht Stenzinger, Farastuk Bozorgmehr, Michael Thomas, Hauke Winter, Michael Allgäeuer, Alexander Schramm, Servet Bolukbas, Marietta Kirchner, Martin Schuler, Petros Christopoulos, Marc Schneider, Romina M Roesch, Johannes Schnorbach, Laura V Klotz, Raffaella Griffo, Marcel Wiesweg, Fabian Doerr, Balazs Hegedüs, Jelena Cvetkovic, Martin E Eichhorn, Florian Eichhorn

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial

    Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial by Albrecht Stenzinger, Dirk Jäger, Michael Thomas, Hauke Winter, Helge Bischoff, Uwe Haberkorn, Felix Herth, Pornpimol Charoentong, Petros Christopoulos, Rajkumar Savai, Laura V Klotz, Raffaella Griffo, Martin E Eichhorn, Florian Eichhorn, Benedikt Niedermaier, Philip Baum, Michael Allgäuer, Marc A Schneider, Claus-Peter Heußel, Maria Paula Roberti, Inka Zoernig

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: